Investigating how SERPINB3 affects cervical cancer treatment resistance
The role of SERPINB3 in cervical cancer therapeutic resistance
This study is looking at a protein called SERPINB3 that makes cervical cancer cells tougher against radiation treatment, and by figuring out how to reduce its effects, researchers hope to help patients with this type of cancer respond better to radiation therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11181506 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of SERPINB3, a protein linked to resistance against radiation therapy in cervical cancer. By using advanced techniques like CRISPR-Cas9 to knock out SERPINB3, researchers aim to make cervical tumor cells more susceptible to radiation-induced cell death. The study will explore how targeting SERPINB3 can change the tumor environment and enhance the effectiveness of radiation therapy. Patients may benefit from insights into new treatment strategies that could improve outcomes for those with SERPINB3-high tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cervical cancer exhibiting high levels of SERPINB3.
Not a fit: Patients with cervical cancer who do not have high SERPINB3 levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for cervical cancer patients who currently struggle with therapy resistance.
How similar studies have performed: Previous research has shown promising results in targeting similar biomarkers to enhance cancer treatment effectiveness, suggesting a potential for success in this approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Markovina, Stephanie — Washington University
- Study coordinator: Markovina, Stephanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.